FR3004341A1 - COSMETIC COMPOSITIONS COMPRISING QUERCETIN DIMER AS ACTIVE INGREDIENT - Google Patents

Abstract

The subject of the invention is a cosmetic and / or dermatological composition. The composition comprises, as active ingredient, an oligomer of quercetin, said oligomer being endowed with an action on the factor KEAP1 and it comprises 0.2 to 2% by weight of a solution containing a solids content of 0, 1 to 1% by weight, wherein the oligomer represents 3 to 30% by weight of the dry extract. Application of oligomers of quercetin, in particular dimer, to the treatment of cutaneous affections.

Description

The technical field of the present invention is that of cosmetic and / or dermatological compositions comprising, as active ingredient, polyphenols, in particular flavonoids, and most particularly quercetin oligomers. Polyphenols form a class of compounds of particular interest for applications in the cosmetic field for skin care. Among this vast family of molecules, quercetin is widely used in cosmetics and dermatology, particularly for its anti-radical and anti-inflammatory properties. Indeed, quercetin is one of the most common molecules found in the plant kingdom. It has many biological properties related to its polyphenolic groupings. Quercetin is a flavonol, flavonols being included in flavonoids, flavonoids representing a class of polyphenols. The representation of the molecular structure of quercetin is given below: It is known that in general, an oligomerized form amplifies the biological effects of the corresponding monomer. We can cite a dimer of resveratrol, the delta viniferine, which has more powerful biological effects than its monomer resveratrol. As an example, reference can be made to patent FR-2975592.

This does not seem to be the case with quercetin, because on the one hand there are few publications on the possibility of making quercetin dimers and, on the other hand, no use of dimers has been proposed to date. In addition, no cosmetic and / or dermatological composition containing a quercetin dimer has been placed on the market. However, hemoproteins have been reported to be able to dimerize quercetin, such as cytochrome c, hemoglobin and myoglobin (Usanov SA et al., Oxidative modification of quercetin by hemeproteins, Biochemical and biophysical research communications, 2006, 342, pp. 459-464, and Corrigendum 2007, 353, 848), as well as an iron complex K3 [Fe (CN) 6] usable with an organic solvent (Oligomeric oxidation products of the flavonoid quercetin, Chemistry of Natural Compounds, 2008 44, No. 4, pp. 427-431). The only indication of use of the quercetin dimer in these publications is the advancement of the oxidation reaction of quercetin monomer. It has also been demonstrated that it is possible to polymerize flavonoids but only glycosylated, such as rutin (quercetin-3-rutinoside), via recombinant laccase from M. thermophila whose trade name is Suberase® and also via laccases from Pycnoporus sanguineus and Pycnoporus coccineus (Appl Microbiol Biotechnol 2011, 90, 97 and FR2944794). It has also been proposed to use certain flavonoid glycosides, including rutin, in applications in cosmetics, particularly in the anti-aging, protection of sensitive skin and anti-inflammatory areas.

The conversion of quercetin to oligomers using laccase from M. thermophila yields no result. For the reaction to work, it seems that the presence of a sugar attached to quercetin is necessary. Quercetin oligomers have, however, been previously described in the literature using the Ustilago maydis microorganism. (Biomacromolecules, 2006, 6, 1845). It has been shown that these oligomers as food additives, would have improved antioxidant activities compared to quercetin monomer as generally in polyphenols. The object of the present invention is to provide an oligomer of quercetin suitable for use in a cosmetic and / or dermatological composition whose action is at the cellular level. In the present invention, the Applicant has surprisingly found that quercetin is an excellent substrate for laccase from Botrytis cinerea which is a fungus found in certain grape vines, which has made it possible to obtain a quercetin dimer with an interesting yield that can be used in the cosmetics sector. In particular, the dimer of quercetin has been prepared and incorporated into cometic and / or dermatological compositions. The structure of the quercetin dimer is shown below: The dimer thus obtained has led to excellent results in dermal application in the field of anti-aging, in particular in the fight against inflammatory phenomena, due in particular external aggressions such as UV. Even more surprisingly, the applicant has found that quercetin has no effect on the HO factor KEAP-1, while the dimer modifies this factor in unexpected proportions. The subject of the invention is therefore a cosmetic and / or dermatological composition characterized in that it comprises, as active ingredient, an oligomer of quercetin, said oligomer being endowed with an action on the factor KEAP1. According to one characteristic of the invention, it comprises 0.2 to 2% by weight of a solution containing a solids content of 0.1 to 1% by weight. According to another characteristic of the invention, the oligomer represents 3 to 30% by weight of the dry extract. According to yet another characteristic, the composition comprises 1% of the solids solution, the composition being in the form of an anti-aging cream for mature skin. According to yet another characteristic, the composition comprises 0.5% of the solids solution, the composition being in the form of a hand cream. According to yet another characteristic, the composition comprises 2% by weight of the solids solution, the composition being in the form of an anti-aging cream for sensitive skin. The composition may comprise 0.8% by weight of the solids solution, the composition being in the form of an anti-aging cream for sensitive skin. The composition may comprise 1.7% of the solids solution, the composition being in the form of an anti-aging cream for sensitive skin. The invention also relates to a process for the preparation of oligomers of quercetin characterized in that a reaction medium consisting of one half of a solution containing the laccase resulting from the fermentation of Botrytis cinerea is reacted in a fermenter and for another of a plant extract containing the quercetin-type substrate previously solubilized in ethanol, and then when the degree of conversion of quercetin reaches 40 to 95%, the reaction is stopped by thermal denaturation of the laccase, then the medium The reaction is filtered in order to purify the oligomers obtained. According to one characteristic of the process, the ethanol is distilled and replaced by another alcohol, such as propane-1,35 diol to obtain a dry extract. The plant extract containing quercetin may be derived from the plant Sophora japonica. The temperature of the reaction medium can be maintained between 20 ° C. and 30 ° C. The quercetin oligomers are purified, for example, by HPTLC and lyophilized to obtain a powder having a purity greater than 95%. The dry extract obtained advantageously contains 5 to 18% by weight of quercetin dimer. The invention also relates to the use of the quercetin dimer obtained according to the above process for the preparation of cosmetic and / or dermatological compositions for the treatment of inflammatory skin phenomena. A very first advantage of the present invention lies in the anti-inflammatory activity of quercetin oligomers at KEAP1 level. Another advantage of the present invention lies in obtaining an oligomer, in particular the dimer, which can be used industrially in cosmetology. Another advantage of the present invention is the purity of the oligomers obtained. Another advantage lies in the absence of side effects of the oligomer and in particular the dimer. Yet another advantage of the invention is the purity of the resulting oligomer which can be used as in a cosmetic composition. Other features, advantages and details of the invention will be better understood on reading the additional description which follows. As previously explained, quercetin in itself has no effect on the KEAP1 marker translating action at the cellular level.

This marker makes it possible to translate the phenomena of cutaneous degradation (Kaspar JW et al in Free radical biology and medicine A., 2009, 47, 1304), but also to report on the problems related to sensitive skin (Natsch A. Toxicological Sciences 2010 , 113, 284). In the context of a cutaneous aggression, as for example with the UV, the level of the KEAP-1 factor must be lowered in order to allow the skin to better resist and defend itself against this aggression.

To evaluate the anti-aging potential of the oligomers, in particular the quercetin dimer, a test measuring this marker on skin explants with topical application was performed. The same test was applied with quercetin to compare its effect on KEAP-1 with that of its dimer. The KEAP-1 marker (Kelch-like ECH-Associated Protein-1) was visualized during all the tests carried out by using the oligomers, in particular the dimer, in the cosmetic compositions cited by way of example. . In order to prepare the oligomers used in the cosmetic and / or dermatological compositions according to the invention, the procedure is as follows or in an equivalent manner.

A reaction medium consisting of half a solution containing laccase resulting from the fermentation of Botrytis cinerea, and the other of a plant extract containing the quercetin substrate previously solubilized in ethanol, is introduced into a fermenter. It is a question of reacting this reaction medium in the presence of this laccase. The conversion reaction is conducted at a temperature of the order of 20 to 30 ° C. The rate of transformation of quercetin is monitored and when this level reaches 40 to 95% of the initial mass of the plant extract, the reaction is stopped by thermal denaturation of the laccase. The reaction medium thus obtained is then filtered in order to purify the oligomer or oligomers formed.

It should be noted that the degree of conversion of quercetin varies according to the desired purity of oligomer, in particular dimer. Thus, it can be considered that a conversion rate of 40% is obtained approximately after 12 hours and a conversion rate of 95% is also obtained approximately after 48 hours. Ethanol is distilled and replaced with another alcohol, such as propane-1,3-diol. The solids-containing solution contains 3 to 30%, and preferably 5 to 18%, by weight of quercetin oligomers, predominantly dimer. Advantageously, the plant extract containing quercetin is derived from the plant Sophora japonica. Quercetin oligomers may also be purified preferably by high pressure liquid chromatography (HPTLC) and freeze-dried to obtain a powder having a purity greater than 95%. The dry extract is used in solution in a proportion of between 0.1 and 1% with a concentration of quercetin dimer in this dry extract ranging from 3 to 30%. It has been noted that a higher concentration of dry extract ultimately leads to a precipitate of the oligomer during the preparation of the cosmetic composition and this is not conceivable for subsequent cosmetology applications. The reaction is monitored by HPLC and the conversion rate is determined as a function of the integrated area of the quercetin peak during the reaction. The quercetin dimer may also be completely purified by HPTLC and lyophilized to yield a powder with a purity greater than 95%. However, for economic reasons, it is the diluted form described above which will be preferentially used, in particular in cutaneous biological tests. Thus, in the compositions according to the invention, the active ingredient is the starting substrate, converted to quercetin dimer at a conversion rate ranging from 40 to 95%. The dimerization was visualized by liquid chromatography coupled to mass spectrometry. (Ion m / z 603 is C30H18014, corresponding to the oligomerization of two quercetin molecules). To highlight the impact on the KEAP1 marker, a number of tests are performed on skin explants. It should be noted that the marker KEAP1 is a protein involved in various pathways at the cutaneous level, reflecting the aggression of the skin at the cellular level. Preparation of explant explants with a diameter of about 11 mm (± 1 mm) were prepared from an abdominal plasty of a 59-year-old woman. The explants were kept alive in BEM (BIO-EC's Explants Medium) at 37 ° C in a humid atmosphere, enriched with 5% CO2.

An extract of Sophorica japonica at a concentration of 0.3% dry extract with 6% quercetin is prepared. Half will be used directly in the test to compare it with a quercetin oligomer extract, especially dimer. The other half is transformed by the action of laccase from Botrytis cinerea with a conversion rate of quercetin of 84% into oligomers, in particular dimer. This leads to a concentration in the solids content of 5% by weight quercetin dimer. The comparison is made in quercetin equivalent monomer, otherwise it would be 2.5% because the molecular weight of the dimer is obviously double the monomer. The explants of the test are distributed as follows: Distribution of explants in 6 batches, as follows Treatments Explant No. Stop (s) TO Freeze 3 TO or formalin T None 3 J8 Fold Product 1 concentration 1 3 J8 P12 Product 1 concentration 2 3 J8 P21 Product 2 concentration 1 3 J8 P22 Product 2 concentration 2 3 J8 The product Pl1 therefore represents a formula at 0.5% of a 0.3% by weight solution of solids containing quercetin dimer at concentration of 5% by weight of this dry extract (with a residue of 1% of unprocessed quercetin), or 7.5.10-5% of dimer. The product P12 therefore represents a 1% formula of a solution containing 0.3% by weight of solids containing quercetin dimer at a concentration of 5% by mass of this dry extract (with a residue of 1% of unchanged quercetin), ie 1.4 × 10 -4% of dimer. The product P21 therefore represents a 0.5% formula of a 0.3% by weight solution of dry extract containing quercetin at a concentration of 6% by weight of this dry extract, namely 9.10-5% of quercetin. The product P22 therefore represents a 1% formula of a solution containing 0.3% by weight of solids content containing quercetin at a concentration of 6% by mass of this dry extract, ie 1.8 × 10 -4% of quercetin. . Application of Oligomerized Products The treatment was carried out at 0, 3, 6 and 7 by topical application of 2 mg by explant of the products to be tested, spread with a small spatula on the explants. Explants from lot T received no treatment. Samples At OJ, the explants in Lot TO were taken and cut in half. One half was fixed in buffered formalin and the other half was frozen at -80 ° C. On day 8, the 3 explants of each lot were removed and treated as previously indicated. Histological treatments After 24 hours of fixation in buffered formalin, the samples were dehydrated and impregnated in paraffin using a Leica TP 1010 dehydration automaton. These 10 samples were put in bulk using a Leica EG 1160 coating station. 5 μm sections were made using a Minot microtome, Leica RM 2125 and mounted on Superfrost® plus silanized glass slides. Microscopic observations were made by transmission light microscopy. The shots were taken with a Leica DMLB or Orthoplan microscope equipped with an Olympus DP72 digital camera driven by Olympus CellD acquisition and archiving software. The formula used in the Explant Application has the following composition: COMPOUND NAMES COMPOUNDS% FATTY PHASE Isofol 20 (Sasol) Octyldodecanol 5.00 AQUEOUS PHASE Demineralized Water Water Qsp 100 Microcare PM 4 (Thor) 2-Phenoxyethanol Methylparaben / ethylparaben / butylparaben / propylparaben / 0.30 Sepigel 305 (Seppic) Polyacrylamide / 14 isoparaffin / Laureth-7 C13- 1.50 Examination of the general morphology and quantification of KEAP1 The general morphology was examined on paraffin sections stained with Goldner's variant Masson trichrome to verify that there was no particular problem, and the KEAP1 marker was then quantified by immunostaining. Result on the marker KEAP1 Variation of the expression of KEAP1 to J8 compared to the untreated control (TJ8) and after 8 days of treatment: - The product Pll induces a decrease of 30%. - The product P12 induces a decrease of 25%. - The product P21 induces a decrease of 2%. - The product P22 induces a decrease of 3%. Surprisingly, at the two concentrations tested in topical application, the quercetin dimer obtained thus induces a significant decrease in the expression of KEAP1 unlike quercetin monomer which has no activity in this biological pathway, that is to say say at the cellular level. Since the KEAP1 marker is a protein implicated in different pathways at the cutaneous level, the result obtained with the quercetin dimer is a good compound for its use in protecting the skin against external aggressions, for example with UV, or in the skin. the framework of its use to protect sensitive skin. In the formulations, the use concentration of the diluted product of the formula varies between 0.2 and 2% of a solution with a solids content of between 0.1 and 1% by weight containing between 3 and 30% of quercetin dimer with preferably between 5 and 18%, that is to say between 6.10-6% and 6.10-3% quercetin dimer in total in the formula with preferably between 1.10-5% and 3.6.10-3%. A number of cosmetic and / or dermatological compositions containing quercetin dimer and having the following composition have been prepared.

It goes without saying that the cosmetic composition according to the invention can be prepared in all the usual forms, for example in the form of cream or gel, or others. Example 1: Anti-Aging Cream Mature Skin COMMERCIAL NAMES% COMPOUNDS PHASE A Natragem EW-FL (Croda) 5.00 Glyceryl Stearate / Polyglyceryl-6 Palmitate / Succinate / Cetearyl Alcohol Hydracire S (Gattefossé) 2.00 Acacia decurrens / Jojoba / Sunflower seed wax / Polyglyceryl-3 esters Compritol 888 (Gattefossé) 2.00 Glyceryl dibehenate / Tribehenin / Glyceryl Behenate Tegosoft CR (Evonik) 2.00 Cetofleate Ricinoleate Isofol 20 (Sasol) 3.00 Octyldodecanol Cetiol CC ( BASF) 2.50 Dicaprylyl Carbonate DC EL 7040 (Dow Corning) 2.00 Caprylyl methicone / PEG-12 Dimethicone / PPG-20 Crosspolymer DC PH 1555 HRI (Dow 2.00 Trimethyl pentaphenyl trisiloxane Corning) Omega 9 Ceramide (Solabia) 1.00 Olive oil Aminopropanediol esters PHASE B Demineralized water Qs 100 Microcare water PM 4 (Thor) 0.80 Phenoxyethanol / methylparaben / ethylparaben / butylparaben / propylparaben Glycerin (Interchemy) 4.00 Glycerin PHASE C Oligo-quercetin ( Ground abia) 1.00 PHASE D Novemer EC-2'polymer (Noveon) 1.15 Sodium acrylates / Beheneth-25 methacrylate crosspolymer / Hydrogenated polydecene / Lauryl glucoside Fragrance 0.20 Perfume Example 2: Hand cream, COMMERCIAL NAMES% COMPOUNDS PHASE A GenioCare El (Akott) 4.00 Cetearyl alcohol / Sorbitan stearate / Sodium lauroyl lactylate / Caprylic / capric triglycerides / hydrogenated lecithin Nacol 22/98 2.00 Behenyl alcohol White beeswax (Interchemy) 2.00 Cera alba White Vaseline P23 (Aiglon) 2.00 Petrolatum Vaseline Oil 2.00 Paraffineum liquidum fluid (Aiglon) Isofol 20 (Sasol) 4.00 Octyldodecanol DC 200 V 100 (Dow Corning) 1.50 Dimethicone PHASE B Demineralized water Qs 100 Water Microcare PM 4 (Thor) 0.80 Phenoxyethanol / methylparaben / ethylparaben / butylparaben / propylparaben Butylene glycol (Interchemistry) 1.00 Butylene glycol Glycerin (Interchemy) 5.00 Glycerin Keltrol CG-SFT (CP Kelco) 0.20 Xanthan gum PHASE C Glycofilm (Solabia ) 3.00 Biosaccharide Gum-4 PHASE D Quercetin Oligo-Quercetin (Solabia) 0.50 Sepigel 305 (Seppic) 0.50 Polyacrylamide / C13-14 Isoparaffin / Laureth-7 Citric Acid, 10% Solution 0.24 Citric Acid Perfume 0.20 Perfume Example 3: anti-aging cream for sensitive skin COMMERCIAL NAMES% COMPOUNDS PHASE A Montanov 202 (Seppic) 5.00 Arachidyl alcohol / behenyl alcohol / arachidyl glucoside Nikkolipid 81 S (Nikko) 0.30 Batyl alcohol / acid stearic / caprylic / capric triglyceride / lecithin Miglyol 812 (Sasol) 4.00 Caprylic / capric triglyceride Isofol 20 (Sasol) 3.00 Octyldodecanol Tegosoft CO (Goldschmidt) 2.00 Cetyl ethylhexanoate Dub PTO (Stearinyls) 2.00 Pentaerythrityl tetraethylhexanoate Dubois) Ç6 Ceramide from 0.30 Palmitoyl PG-linoleamide Cotton oil (Solabia) punicic acid-rich ceramide analogue obtained from pomegranate seed oil 1.00 Phytopin (DRT) 0.30 Phytosterols PHASE B Demineralized water qsp Water Conservative qs Quercetin Oligo (Solabia) 2.00 Glycerin 2.00 Glycerin Keltrol CG SFT (Kelco) 0.20 Xanthan Gum PHASE C Fucogel (Solabia) 5.00 BioSaccharide Gum-1 PHASE D Papaya Glycolysate (CEP) 4 , 00 Propylene glycol / Water / Carica papaya Simulgel NS (Seppic) 0.75 Hydroxyethyl acrylate / sodium acryloyldimethyl taurate copolymer / squalane / Polysorbate 60 DC 1501 (Dow Corning) 1.00 Cyclopentasiloxane / dimethiconol PHASE E Flashy Fragrance (Synarome) 0,20 Perfume DC Yellow 6 (LCW) qs CI 15985 FDC Red 40 (LCW) qs CI 16035 Example 4: anti-aging cream for sensitive skins COMMERCIAL NAMES% COMPOUNDS PHASE A Montanov 202 (Seppic) 5.00 Arachidyl alcohol / Alcohol behenyl / arachidyl glucoside Nikkolipid 81 S (Nikko) 0.30 Batyl alcohol / stearic acid / caprylic / capric triglyceride / lecitin Miglyol 812 (Sasol) 4.00 Caprylic / capric triglyceride Isofol 20 (Sasol) 3.00 Octyldodecanol Tegosoft CO (Goldschmidt ) 2,00 Cetyl Ethylhexanoate Dub PTO (Stearinys 2) Dubois) Q6 Ceramide from 0.30 Palmitoyl PG-linoleamide Cotton oil (Solabia) punicic acid-rich ceramide analog obtained from pomegranate seed oil 1.00 Phytopin (DRT) 0.30 Phytosterols PHASE B Demineralized water qs Aqua Preservative Qs Oligoquercetin (Solabia) 0.80 Glycerin 2.00 Glycerin Keltrol CG SFT (Kelco) 0.20 Xanthan gum PHASE C Fucogel (Solabia) 5.00 Biosaccharide gum -1 PHASE D Papaya Glycolysate (CEP) 4.00 Propylene Glycol / Aqua / Carica papaya Simulgel NS (Seppic) 0.75 Hydroxyethyl acrylate / sodium acryloyldimethyl taurate copolymer / squalane / Polysorbate 60 DC 1501 (Dow Corning) 1, 00 Cyclopentasiloxane / dimethiconol PHASE E Flashy Parfum (Synarome) 0.20 DC Yellow 6 Perfume (LCW) Qs CI 15985 FDC Red 40 (LCW) Qs CI 16035 Example 5: Anti-Aging Cream for Sensitive Skin COMMERCIAL NAMES% COMPOUNDS PHASE A Montanov 202 (Seppic) 5.00 Arachidyl alcohol / alcohol beh enylic / arachidyl glucoside Nikkolipid 81 S (Nikko) 0.30 Batyl alcohol / stearic acid / caprylic / capric triglyceride / lecitin Miglyol 812 (Sasol) 4.00 Caprylic / capric triglyceride Isofol 20 (Sasol) 3.00 Octyldodecanol Tegosoft CO (Goldschmidt ) 2,00 Cetyl Ethylhexanoate Dub PTO (Stearinyseries 2,00 Dubois pentaerythrityl tetraethylhexanoate) Ç6 Ceramide from 0,30 Palmitoyl PG-linoleamide Cotton oil (Solabia) analog of ceramide rich in punicic acid obtained from Pomegranate seed oil 1.00 Phytopin (DRT) 0.30 Phytosterols PHASE B Demineralized water Qsp Preservative water qs Oligo-quercetin (Solabia) 1.70 Glycerin 2.00 Glycerin Keltrol CG SFT (Kelco) 0.20 Xanthan gum PHASE C Fucogel (Solabia) 5.00 BioSaccharide Gum-1 PHASE D Papaya Glycolysate (CEP) 4.00 Propylene Glycol / Aqua / Carica papaya Simulgel NS (Seppic) 0.75 Hydroxyethyl acrylate / sodium acryloyldimethyl taurate copolymer / Squalane / Polysorbate 6 0 DC 1501 (Dow Corning) 1.00 Cyclopentasiloxane / dimethiconol PHASE E Flashy Parfume (Synarome) 0.20 DC Yellow 6 Perfume (LCW) Qs CI 15985 FDC Red 40 (LCW) Qs CI 16035 RESULTS The compositions thus prepared were tested on volunteer subjects by topical application and the following procedure was followed. The compositions described above were tested against a placebo in a double blind study on 20 volunteers to evaluate the known effects of UV in cutaneous aging phenomena. A dose of UV 10 corresponding to the minimum erythemal dose was applied to each of the volunteers at OJ. The application of the cosmetic products according to the examples given is then carried out at a rate of 2 times a day for 4 weeks. The evolution of the various parameters at the level of the color of the skin was followed on day 28. These parameters are a * chromaticity coordinates (red-green axis) and associated I.T.A angle (Individual Typological Angle). These very sensitive parameters reflect in particular a phenomenon of cutaneous aging. A highly significant beneficial effect (p <0.001, Anova method) was shown with each of the formulations containing quercetin oligomers, hence dimer, which proves an anti-aging result of these quercetin oligomers.

The cosmetic compositions according to the invention thus provide a certain advance in the treatment of cutaneous aging.

Claims (10)

REVENDICATIONS1. Cosmetic and / or dermatological composition characterized in that it comprises, as active principle, an oligomer of quercetin, said oligomer being endowed with an action on the factor KEAP1. 2. Cosmetic and / or pharmaceutical composition according to claim 1, characterized in that it comprises 0.2 to 2% by weight of a solution containing a solids content of 0.1 to 1% by weight. 10 3. Cosmetic and / or pharmaceutical composition according to claim 2, characterized in that the oligomer represents 3 to 30% by weight of the dry extract. 4. Cosmetic and / or dermatological composition according to claim 2 or 3, characterized in that it comprises 1% of the solids solution, the composition being in the form of an anti-aging cream for mature skin. . 5. Cosmetic and / or dermatological composition according to claim 2 or 3, characterized in that it comprises 0.5% of the solids solution, the composition being in the form of a hand cream. 6. Cosmetic and / or dermatological composition according to claim 2 or 3, characterized in that it comprises 2% of the solids solution, the composition being in the form of an anti-aging cream for sensitive skin. 25 7. Process for the preparation of oligomers of quercetin characterized in that a reaction medium consisting of one half of a solution containing the laccase resulting from the fermentation of Botrytis cinerea is reacted in a fermenter and the other of a a plant extract containing the quercetin-type substrate previously solubilized in ethanol, and then when the degree of conversion of quercetin reaches 40 to 95%, the reaction is stopped by thermal denaturation of the laccase, then the reaction medium is filtered in order to purify the oligomers obtained. 8. Process for the preparation of quercetin oligomers according to claim 7, characterized in that the ethanol is distilled and replaced by another alcohol, such as propane-1,3-diol to obtain a dry extract. 9. Preparation process according to claim 7 or 8, characterized in that the dry extract obtained contains 3 to 30%, and preferably 5 to 18%, by weight of quercetin dimer. 10. Use of the quercetin dimer obtained according to any one of claims 7 to 9 for the preparation of cosmetic and / or dermatological compositions for the treatment of cutaneous aging phenomena.